Alnylam Pharmaceuticals · 4 hours ago
Scientist, Antibody Conjugation
United States
Full-time
Remote
Mid Level
$110K/yr - $166K/yr
0+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, seeking a Scientist to join their Protein Sciences group focused on antibody conjugation. The role involves performing chemical reactions, optimizing methods, and collaborating with cross-functional teams to drive research projects.
BiotechnologyHealthcarePharmaceuticalHealth CareMedicalTherapeutics
No H1B
Responsibilities
Perform chemical reactions to assemble antibody-oligonucleotide conjugates using various conjugation handles, linkers, and antibody formats (IgG, Fab, scFv, bispecific)
Utilize multiple strategies for stochastic and site-specific conjugation
Optimize reactions and purification methods to improve yields and efficiency ranging from mg to gram scale
Independently troubleshoot conjugation reactions for improved yields and processes
Analyze conjugates using all relevant techniques (IEX, HIC, SEC, SDS-PAGE, mass spec, UV-Vis)
Understanding of antibody design and cloning is nice to have
Understanding of antibody ligand/target validation using BLI and SPR for kinetic analysis is nice to have
Drive automation for high-throughput conjugation at various scales
Work closely with biology teams to plan studies and generate materials on time for multiple projects
Proper electronic notebook record keeping with high attention to detail
Communication of experimental plans and data to multiple cross-functional scientific teams
Work closely with biologists, chemists, and pharmacologists to contribute to the strategic direction of research programs across multiple therapeutic modalities
Qualification
Required
The candidate should have a PhD degree with 0-3 years of relevant experience
Strong understanding of antibody conjugation chemistries with both stochastic and site-specific techniques
Strong understanding of modern ADC chemistry and linker design highly preferred
Hands on experiences with preparing antibody-drug conjugates and analyzing them using multiple methods (IEX, HIC, SEC, mass spec)
0-2 years of pharmaceutical or biotechnology industry experience is preferred
Experience with Agilent and AKTA software
Experience with recombinant protein analysis (affinity, size exclusion, reverse phase, hydrophobic interaction, ion exchange chromatography, SDS-PAGE, and UV-VIS spectroscopy)
Passionate about driving his or her projects to independently contribute to research directions and solve challenging issues
Detail oriented, self-motivated, and comfortable working with highly technical projects
Ability to work on multiple projects simultaneously and deliver conclusive results
Highly adaptable and responsive to new priorities in a fast-paced environment
Ability to train and supervise associate scientists in the laboratory
Effective written and oral communication skills
Experience with ELN record keeping
Experience preparing and presenting using PowerPoint software
Team oriented with strong work ethic
Preferred
Understanding of antibody design and cloning is nice to have
Understanding of antibody ligand/target validation using BLI and SPR for kinetic analysis is nice to have
Experience with SPR and/or Octet binding experiments is nice to have
Benefits
Annual short-term incentive award (e.g., bonus or sales incentive)
Annual long-term incentive award (e.g., equity)
Medical, dental, and vision coverage
Life and disability insurance
Lifestyle reimbursement program
Flexible spending and health savings accounts
401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
BioWorld Financial Watch
2026-07-18
2026-07-10
Company data provided by crunchbase